Sign in
ImmunologyVaccine
Peer-reviewed journal article

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

K. W. Peng, T. Carey, P. Lech, R. Vandergaast, M. A. Munoz-Alia, N. Packiriswamy, C. Gnanadurai, K. Krotova, M. Tesfay, C. Ziegler, M. Haselton, K. Sevola, C. Lathrum, S. Reiter, R. Narjari, B. Balakrishnan, L. Suksanpaisan, T. Sakuma, J. Recker, L. Zhang, S. Waniger, L. Russell, C. Petro, C. A. Kyratsous, A. Baum, , S. J. Russell

Abstract

An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.